{"id":"W3032247240","doi":"10.1200/jco.2020.38.15_suppl.e21683","title":"Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Clinical endpoint; Ipilimumab; Taxane; Oncology; Interim analysis; Lung cancer; Progressive disease; Phases of clinical research; Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Cancer; Immunotherapy; Breast cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004597657,0.00123914,0.002093617,0.0002914545,0.0004279762,0.00114473,0.0006206373,0.00143077,0.005307506],"category_scores_gemma":[0.002230379,0.0004458782,0.001265081,0.0002126579,0.0008506188,0.0009995035,0.0004606335,0.002366961,0.0008486301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004959915,"about_ca_system_score_gemma":0.001376148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003160829,"about_ca_topic_score_gemma":0.0008170172,"domain_scores_codex":[0.9990436,0.0005811342,0.00005377401,0.0001003782,0.00006796116,0.0001529908],"domain_scores_gemma":[0.9985349,0.0004885022,0.0002861198,0.0001070348,0.00008482814,0.0004985295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9197544,0.0127216,0.005061986,0.0008837504,0.002178631,0.0002596574,0.0001307995,0.002317134,0.006386193,0.0003810983,0.0106599,0.03926493],"study_design_scores_gemma":[0.8338766,0.1517039,0.00668159,0.00006310952,0.0009974946,0.0002177953,0.00003042052,0.001127673,0.001314618,0.0005894857,0.003373067,0.00002420954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9619586,0.008763034,0.00240051,0.002833914,0.0008008606,0.006558845,0.005884499,0.0002304087,0.01056929],"genre_scores_gemma":[0.9683534,0.002395796,0.004244311,0.002938056,0.0006974151,0.008274351,0.007610041,0.00007967522,0.005406916],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005307506,"threshold_uncertainty_score":0.02431506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1198119733716877,"score_gpt":0.4534532654417884,"score_spread":0.3336412920701007,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}